Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments. It’s Sanders’ latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies.
The city of Baltimore's lawsuit contended Biogen paid the companies to “manipulate” placement of generic versions of ...
The PBMs say out-of-pocket insulin costs have fallen sharply since 2019. The Pharmaceutical Care Management Association, ...
The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of ...
Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.
In a move to address escalating insulin prices, the Federal Trade Commission (FTC) has initiated action against the three ...
FTC files lawsuit against top PBMs and GPOs for alleged anticompetitive practices in inflating insulin prices. Learn about the allegations and responses.
The industry is reaching a tipping point where an increasingly loud chorus of voices are demanding transparency and a focus ...
The US Federal Trade Commission said that CVS Health's Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback